WVP
GANX icon

Worth Venture Partners’s Gain Therapeutics GANX Stock Holding History

Worth Venture Partners’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,532
Closed -$232K – 123
2021
Q1 		$232K Buy
+15,532
New +$204K 0.11% 92

Other funds holding GANX

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $2.66B AUM 26.89% 1-Year Est. Return

Worth Venture Partners's GANX Position: Q2 2021 in Review

Worth Venture Partners sold out of Gain Therapeutics (GANX) in Q2 2021, closing a stake of 15,532 shares — an estimated $232K sold.

Worth Venture Partners first reported a position in GANX in Q1 2021 and held it in 1 quarter. The position peaked at $232K in Q1 2021. 14 funds tracked by Wall St. Rank hold GANX as of Q2 2021.

  • Worth Venture Partners reported no remaining Gain Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Worth Venture Partners sold 15,532 Gain Therapeutics shares in Q2 2021, an estimated $232K.
  • Worth Venture Partners first reported a position in Gain Therapeutics in Q1 2021 and held it in 1 quarter.
  • Worth Venture Partners's Gain Therapeutics position peaked at $232K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2021.

Based on Worth Venture Partners's 13F filing for Q2 2021, filed 16 Aug 2021.